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Abstract
Sortase A is a powerful protein engineering tool that cleaves proteins and attaches them
to an acyl acceptor of choice. However, the most active wild type variants of sortase A only
show high activity at a limited number of cleavage motifs, and so work is underway to create a
variant of sortase A that shows high activity at a greater variety of cleavage sites. Additionally,
current studies attempting to optimize the enzyme require a way to stabilize an unstructured loop
for the crystallization, in order to collect X-ray diffraction structural data. Here, preliminary
results from the design of an “loop-swapped” sortase A enzyme variants are discussed, as well as
the synthesis of two different thiol-containing “trapping” peptides intended to freeze sortase A in
its bound conformation via a covalent disulfide bond. The first peptide is a previously described
unnatural peptide, and was discontinued before completion, and the second peptide is a natural
peptide which was completed and purified. Future work will involve the co-crystallization of this
peptide with “loop-swapped” sortase A variants.
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Introduction
Sortase A (SrtA) is a transpeptidase enzyme found in gram-positive bacteria which
cleaves proteins at the LPXTG motif and ligates the C-terminal of the cleaved protein onto an
acyl acceptor, lipid II (Figure 1).1,2 Other acyl acceptors such as the N-terminus of another
protein or peptide are also able to accept the cleaved protein.3 This function has been
successfully exploited by researchers as a protein engineering tool to modify protein sequences
post-translationally, attach protein tags to cells, create cyclic structures, and more.
Staphylococcus aureus sortase A (SrtAstaph) represents the most commonly used sortase A, in
particular due to its high cleavage activity. Despite its many uses, SrtAstaph is limited by its
specificity to the LPXTG cleavage motif. The Streptococcus pneumoniae sortase A (SrtAstrep)
recognizes more cleavage motifs, including LPATS and LPATA3, however is less active than the
S. aureus version, with approximately 1/3 cleavage activity when compared to SrtAstaph (Figure
2).

Figure 1. Graphical representation of sortase A catalyzed protein ligation. Figure obtained
from Antos, et al., (2016).
Designing a sortase variant which has the promiscuity (recognition of additional cleavage
sites) of SrtAstrep while maintaining the high activity of SrtAstaph will be beneficial to the research
community as a more flexible protein engineering tool. The activity and promiscuity of new
sortase variants can be tested against peptide variants of the LPXTG motif, via fluorescence
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2assay (Figure 2). This improvement of Sortase A is an ongoing endeavor in the Amacher and
Antos labs, and some parts of the project will be discussed in this paper.
Additionally, structural
characterization of Sortase A while it
is in its bound conformation will
provide insight into the role of the
unstructured β-7/β-8 loop which
appears to play a role in substrate
specificity and cleavage activity. The
Figure 2. Heat map of relative cleavage by sortase A
variants as measured by fluorescent activity. The
single letter labels represent the amino acid in the X
position of the fluorescent peptide Abz-LPATXGK(DNP). Figure created by Izzi Piper.

catalytic residues for SrtAstrep are
C184, H118, and R192. The cysteine,
histidine, and arginine catalytic triad

is conserved in SrtA enzymes of other species. Our hypothesis is that a disulfide bond between
the catalytic cysteine and the LPXTG peptide involved in crystallization will facilitate the
collection of accurate bound-state structural data by both trapping the enzyme in its bound
conformation and preventing peptide shifting. A previous structure of S. aureus SrtA, which
lacked such a covalent bond, revealed a shifted LPETG peptide out of the active site, while a
structure that did contain a covalent bond between its peptide and the active site of sortase did
not have this issue (Figure 3A, B).4,5
The structure PDB ID: 2KID, which is the current best structure of a bound-state sortase A
enzyme, includes the unnatural peptide LPAT*, where T* is an unnatural, thiol-containing
threonine analogue. The authors of Jung, et al., 2005 developed the LPAT* peptide for the
purpose of forming a disulfide bond between sortase and a peptide ligand.1 They showed that a
2

A

B

Figure 3. A. X-ray crystallography structure of SrtAstaph complexed with shifted LPETG
peptide, PDB 1T2W. B. NMR structure of SrtAstaph complexed with (PHQ)LPA(B27) peptide,
PDB 2KID.
disulfide bond did indeed form between the two when the unnatural peptide was added in
excess.1 The goal of the disulfide bond was to allow for the collection of structural data on the
bound enzyme. They had previously synthesized other versions of this threonine analogue
towards the same goal, and found that the resulting bound enzyme was not optimal for structural
studies.1 While their original synthesis of T* began with L-threonine and required nine synthetic
steps, involving the use of highly toxic hydrogen sulfide gas (H2S), the authors designed a new
route in 2012 that was both shorter, requiring only four synthetic steps, and did not require the
use of H2S.1,6 I initially set out to recreate this unnatural peptide following the 2012 synthetic
route, with the ultimate goal of co-crystallizing it with our “loop-swapped” sortase variants in
order to solve X-ray crystallography structures of the bound enzymes. When the synthesis
proved to be unreasonable to complete with the resources available, I created a similar natural
peptide to use towards the same goal.
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Activity of the β-7/β-8 Loop
Previous computational work identified the β-7/β-8 unstructured loop near the active site
of sortase A as quite variable amongst SrtA enzymes, therefore, we hypothesized that it may
affect substrate recognition. The loop is structurally conserved across class A sortases, but varies
greatly in sequence, and sometimes in length. Based on this data, several “loop-swapped” sortase
variants were designed with the body of SrtAstrep and the β-7/β-8 loop from other sortase A
enzymes (Figure 4). The recombinant proteins were expressed using standard protein expression
protocols (Methods).

S. pneumoniae

SPSFaecalis

SPSLactis

SPSMonocytogenes

SPSOralis

SPSAureus

SPSSuis

SPSAnthracis

Figure 4. “Loop Swapped” Sortase A variants with β-7/β-8 Loop in Stick Configuration.
As an example of the naming format, SPSFaecalis stands for ‘S. pneumoniae swap faecalis’,
and indicates that the mutant has the body of S. pneumoniae sortase A and the β-7/β-8 loop
of S. faecalis sortase A. Figure created by Alex Johnson.
Fluorescent peptides were used to mimic the cleavage recognition site of sortase A. Each
peptide followed the sequence Abz-LPAT’XGK(DNP), where Abz is aminobenzoic acid, X
represents any amino acid, and DNP is the chromophore 2,4-dinitrophenol (Figure 5). Abz
fluoresces at 420 nm, and DNP quenches its fluorescence when in close proximity. The peptides
4

were subjected to excitation at 320 nm while in solution with active sortase A variants. Due to
the change in proximity of DNP to Abz during cleavage, fluorescence was quenched in whole
peptides but not in cleaved peptides, and fluorescence signal increased with cleavage activity
(Figure 2).
Our fluorescence data revealed that the cleavage activity and promiscuity of sortase
varied greatly in our different loop-swapped variants, despite all containing the SrtAstrep scaffold.
The activity of the “loop-swapped” variants appears to follow that of the sortase from which the
β-7/β-8 loop came, rather than mimicking the activity of the SrtAstrep base. Multiple “loopswapped” variants showed the high levels of activity at multiple recognition sites, indicating
successful design of a more active and promiscuous enzyme (Figure 2). Work in this area is
ongoing and these results are preliminary.

Fluorescent Peptides
Chromophore-containing peptides for use in the fluorescent sortase A activity assay were
synthesized via solid phase peptide synthesis (SPPS) (Methods). The Abz-LPATAGK(DNP)
peptide was successfully completed and purified (Figure 5A). Due to the presence of the
DNP chromophore, this peptide appears faintly yellow in otherwise transparent solution and
light yellow in powdered form. The mass of this peptide was calculated to be 943.33 Da.
Purification was not performed on the entire crude sample, due to time constraints and the
higher priority of the crystallization peptide. The purified peptide and remaining crude
peptide were not quantified after lyophilization, but the purified peptide was a notably large
amount.

5

The Abz-LPATGGK(DNP) peptide, which mimics sortase A’s natural cleavage motif
without any altered residues, was completed (Figure 5B). A large fraction of the resin was
lost through the filter during the TFA cleavage step of synthesis, meaning that the purified
peptide yield will be decreased. However, it was not purified before the SARS-CoV-2
pandemic halted lab work, and its identity has not been confirmed via MS. Its mass is
calculated to be 929.42 Da.
The Abz-LPATSGK(DNP) peptide was completed (Figure 5C). However, it was not
purified before the SARS-CoV-2 pandemic halted lab work, and its identity has not been
confirmed via MS. Its mass is calculated to be 959.43 Da.
Several times during purification set up, the HPLC showed signs of spiking pressure.
This was troubleshooted by reducing the flow rate, and increasing the flow rate more slowly.
In cases where bubbles entered the line, the system was purged.

6
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Figure 5. Fluorescent peptides used to mimic the sortase A cleavage
motif. Differences between the peptides are highlighted in green. A. The
structure of Abz-LPATAGK(DNP). B. The structure of AbzLPATGGK(DNP). C. The structure of Abz-LPATSGK(DNP).
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Synthesis of a Trapping Peptide: Two Routes

Unnatural Peptide
Following the successful results of the “loop-swapped” variants, bound-state structural data
became important to further understand the interaction of the β-7/β-8 loop with the peptide.
Therefore, synthesis of the unnatural trapping peptide LPAT* was attempted following the
improved 2012 synthesis scheme developed by Jung and Yi (Figure 6A).6

A

B

C

Figure 6. A. Synthetic route for unnatural peptide LPAT*. Figure obtained from Jung and Yi,
(2012). B. Structure of the bis-protected cysteine starting material (compound 13). C.
Structure of the unnatural peptide product (compound 6). The blue rectangle highlights the
part of the starting material conserved, and the green rectangle highlights the reduction of the
starting material’s carboxylic acid.
The first synthetic step, reduction of the cysteine’s C-terminal carboxylic acid, was attempted
three times. In the first attempt, borane tetrahydrofuran complex (referred to as ‘borane’) was
allowed to react with the bis-protected cysteine for 80 minutes total, as described in Methods.
8

This was shorter than the four total hours (1 hour at 0 °C, 3 hours at room temperature)
suggested by Jung and Yi in their 2012 paper.6 The resulting crude product was purified via flash
column chromatography. During purification, thin layer chromatography (TLC) monitoring
showed that the cysteine eluted off the silica gel column in fractions 4 through 7. However, the
TLC did not show a difference between the starting material control sample and the crude
product control sample, and no product was able to be isolated when fractions 4 through 7 were
concentrated. It was determined that the product had been lost.
In the second attempt, the procedure used for synthesis in the first attempt was repeated with
a smaller molar excess of borane, and the crude product was not purified. To determine whether
the reduction reaction had been successful, NMR spectroscopy was performed on both the crude
product and a sample of the starting material. No peak for a carboxylic acid (10 to 12 ppm) was
observed in either spectra, which was unexpected (Figure 7A, B). NMR analysis of the crude
product showed no presence of primary alcohol, indicating that the reduction of the carboxylic
acid failed (Figure 7B). It was then concluded that the first attempt had also failed, and that the
product had not been lost as it was nonexistent. In consultation with mentors, it was determined
that in both cases, the borane had not been allowed to react with the bis-protected cysteine for
long enough.
Following this conclusion, the procedure was repeated and the reaction was allowed to
proceed for one hour at 0 °C and overnight (approximately 17 hours) at room temperature. NMR
spectroscopy was performed on both the crude product and on a new sample of the starting
material, and again no peak for a carboxylic acid (10 to 12 ppm) was observed in either the
starting material or the crude product NMR spectra (Figure 8A, B). The continued absence of the
carboxylic acid peak is unusual and requires further investigation. The NMR spectra of the crude
9

A

B

Figure 7. A. NMR spectrum of bis-protected cysteine starting material, taken at 500 MHz. B.
NMR spectrum of the crude product from synthetic step 1, attempt 2. This spectrum was taken
at 300 MHz on the same day as Figure 7A. Peaks highlighted in red are not present on the
starting material spectrum and are consistent with known chemical shifts of solvent peaks for
MeOH (3.49) and THF (1.85, 3.76).11
product showed some presence of primary alcohol at 3.41-3.44 ppm and 3.62-3.69 ppm,
indicating that the reduction was at least partially successful (Figure 8B). However, the starting
material was clearly still present in the crude product, indicating that conditions for the reduction
need to be improved in order to increase the reaction efficiency.
It is clear that the borane reduction reaction in synthetic step 1 is not optimized for maximum
product yield. In order to understand and improve on these limitations, further investigation is
necessary. Increased length of reaction time did allow the reaction to be successful; however, 17
hours is a very long reaction time and other steps, such as altering the ratio of reaction time at 0
°C versus at room temperature, altering the “room temperature”, altering the molar ratio of bis10

A

B

Figure 8. A. NMR spectrum of bis-protected cysteine starting material, taken at 500 MHz. B.
NMR spectrum of the crude product from synthetic step 1, attempt 3. This spectrum was taken
at 500 MHz on the same day as Figure 8A. Peaks highlighted in red are not present on the
starting material spectrum and are consistent with known chemical shifts of solvent peaks for
MeOH (3.49) and THF (1.85, 3.76).11 Peaks highlighted in green are not present on the
starting material spectrum and are not consistent with solvent peaks. These green peaks are at
chemical shifts (3.41-3.44 and 3.62-3.69), which are consistent with expected peaks from a
primary alcohol on a bis-protected cysteine.
protected cysteine to borane complex, and altering reaction vessel volume, all may lead to
better yields. Further investigation is required to determine how changing these factors affects
the reaction. Additionally, investigation is required into the lack of signal for the carboxylic acid
across all spectra taken. One possible route is confirmation of the bis-protected cysteine’s
formula via mass spectrometry. The synthesis of an unnatural cysteine-containing trapping
peptide was discontinued after the third attempt at synthetic step number one, due to time and
budgetary constraints.
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Natural Peptide
Following termination of synthesis of the unnatural peptide, synthesis of a natural sulfurcontaining peptide was pursued. The natural peptide Bz-GLPACGG-NH2, where Bz is
benzoic acid which does not fluoresce, was synthesized in the same way as the fluorescent
peptides, using SPPS (Methods) (Figure 9A). This “crystallization peptide” was successfully
completed and purified. As it does not contain any chromophores, this peptide appeared clear
in solution, and white in powered form, which is unlike the fluorescent peptides described
earlier in this paper. The mass of this peptide was calculated to be 676.30 Da. Because the
peptide contains a cysteine residue, it has the potential to form self-dimers via disulfide bond
(Figure 9B). The mass of this dimer was calculated to be 1350.58 Da. The monomer and
dimer were both determined, via mass spectrometry, to elute at the same time, and were
collected in the same screw-cap vial. Immediately before the peptide-containing peak, eluted
another high-intensity peak, which was determined to not contain any monomer or dimer of
the desired peptide. It was nonetheless curious due to its high intensity signal and similar
elution time to the peptide. The entire crude peptide solution was purified and lyophilized,
but the resulting powdered peptide was not quantified.
The purification of this peptide encountered the same difficulties involving pressure
spikes that were described earlier in this paper, and approached troubleshooting in the same
way.

12
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Figure 9. A. The structure of monomeric Bz-GLPACGG-NH2. B. The structure of dimeric BzGLPACGG-NH2, showing expected atom connectivity with an exaggerated disulfide bond.
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Future directions
Co-crystallization of the Bz-GLPACGG-NH2 peptide with sortase A variants will be
pursued in future work. Co-crystallization is not anticipated to be attempted with SrtAstrep-based
“loop-swapped” variants, due to the difficulty of crystallizing SrtAstrep in a biological monomer.7
Instead, co-crystallization will be attempted with wild type and potentially also with “loop-swap”
variants of sortase A homologues that have already been shown to crystallize well. The sortase A
homologues of S. agalactiae and of S. mutans have both been shown to crystallize in simple
conditions and are candidates for this future work.8–10
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Methods
Protein expression and purification. Kanamycin-resistant plasmids (Genscript) containing the
hexahistidine-tagged sortase variant genes were expressed in E. coli cells. Cells were grown in
10 ml of LB or 2XYT media with Kanamycin (Kan) (“overnight” culture) for 16 to 18 hours at
37 °C, with shaking, then grown in 1 L of the same media, also with Kan and also at 37 °C, with
shaking, until OD600 readings were between 0.6 and 0.8. Cultures were then induced for
overexpression with isopropylthio-β-D-galactoside (IPTG) and the temperature was lowered to
18 °C. After overexpressing for 18-20 hours, the growth was pelleted via centrifugation, and the
pellet was frozen in liquid nitrogen and stored in -80 °C. The cell pellet was thawed in a roomtemperature water bath, then resuspended in 30 mL of lysis buffer via vortexing. The resulting
cell suspension was lysed via sonication for 30 seconds, two times. This cell lysate was pelleted
via centrifugation. A simplified workflow of this process is presented in Figure 10A.
The supernatant was then run through a nickel column and washed with low imidazole
buffer, then eluted with high imidazole buffer. In some cases, before further purification, the
hexahistidine tag was cleaved using tobacco etch virus protease (TEV protease), and the cleavedsortase containing eluent was run through a second nickel column. Then, the cleaved-sortase
containing wash was further purified via size exclusion chromatography on an ÄKTA prime plus
FPLC, and the monomer-containing fractions were assessed for impurities and preliminary
presence of desired protein via tricine gel electrophoresis. A simplified workflow of this process
is presented in Figure 10B.
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Solid State Peptide Synthesis (SPPS). All natural peptides were synthesized using solid state
peptide synthesis (Figure 11). Each peptide was synthesized in a batch size of 0.1 mmol, using
~0.1724g Rink Amide Resin (resin) as the solid support, with each peptide in its own plastic
synthesis vessel with a 20 μm filter (Resprep) to prevent the evacuation of resin during vacuumdraining. The resin was swollen in excess 1-methyl-2-pyrrolidinone (NMP) before addition of
the first amino acid.
Each amino acid, as well as the resin, contained an N-terminal
Fluorenylmethyloxycarbonyl (Fmoc) protecting group. Prior to each conjugation, the Fmoc
group was cleaved off of the N-terminus of the resin or the most recent amino acid addition
(Figure 11). The resin and attached peptide were washed with an excess of 20% piperidine in
NMP, with rocking at ~65 rpm for 10-20 minutes, two times. The solution was then washed with
NMP with rocking at ~65 rpm for 5 minutes, three times, to remove the free Fmoc group from
solution (Figure 12A). Between each wash, the vessel was vacuum-drained, in order to remove
unwanted chemical debris such as the free Fmoc group and unreacted piperidine.
In a separate vial, the C-terminal amino acid, which was added in 3x molar excess, was
primed using 3x molar excess HBTU and Diisopropylethylamine (DIPEA) (Figure 11). The
amino acid mixture was vortexed to mix, then decanted into the synthesis vessel (Figure 12B, C).
The amino acid vial was washed with NMP to ensure the transfer of all reagents. The resulting
conjugation solution was rocked at ~65 rpm for a minimum of 2 hours. After the conjugation
time was complete, the solution was vacuum-evacuated to remove the byproducts of the
conjugation reaction the solution, then washed with NMP with rocking at ~65 rpm for 10
minutes, three times. Vacuum-draining was also performed between these washes. Abz and Bz
were conjugated using the same method.
16

After each addition, a Kaiser assay was performed, described below. In the event of a
successful result, the conjugation reaction was considered complete, and the process of
conjugating the next amino acid, using the same procedure, was started.
Once all residues and Abz or Bz in a peptide had been conjugated, the completed peptide
was washed with NMP with rocking at ~65 rpm for 10 minutes, three times, to remove chemical
debris from conjugation. Then, the peptide solution was washed with excess DCM with rocking
at ~65 rpm for 10 minutes, three times. Next, the peptide solution was washed in trifluoracetic
acid (TFA), for 30 minutes, two times, in order to cleave the peptide off of the resin. The TFA
washes were performed without rocking, and without a synthesis vessel lid to prevent pressure
buildup. The TFA was then removed from solution via rotovap, and the peptide was added
dropwise to ice cold ether. The ether-peptide solution was centrifuges at 4500 rpm for 5 minutes
at 4 ℃, and the ether supernatant was decanted off. The crude peptide-containing pellet was
vacuum-dried, then stored at 4 ℃ (Figure 12D).

Kaiser Assay. The Kaiser assay is a colorimetric assay that detects the presence of free primary
amines in solution. In the presence of these amines, the solution will turn a distinctive musky
blue color.
The Kaiser test kit consists of three reagents. In order to test each conjugation, 10 μL of
each reagent were pipetted into a clean, labelled microcentrifuge tube, and additionally one tube
for a positive control and one tube for a negative control. These tubes were centrifuged for a few
seconds to ensure that no reagents were on the sides of the tubes. Then, vacuum-dried resin from
the conjugation solution, positive ninhydrin powder, and negative ninhydrin powder, were placed
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into their appropriate tubes, via pipette tip. These tubes were capped, then incubated at 95 ℃ for
5 minutes. A successful result was indicated by no color change in the conjugated resin solution,
which was either clear, or faintly yellow for peptides containing the chromophore DNP. An
unsuccessful result was indicated by a musky blue color.

Mass Spectrometry. Electron Spray Ionization Mass Spectrometry (ESI-MS) was performed on
an Advion Expression Mass Spectrometer. ESI-MS was used to positively identify the presence
of the desired peptide in the initial spectrum collection peaks. The mass found in each collected
peak was compared to the calculated mass of the peptide (ChemDraw).

High Performance Liquid Chromatography Peptide Purification. Peptide purification was
performed on a Dionex UltiMate 3000 UHPLC with Diode Array detector. The crude peptide
was dissolved in just enough 1:1 acetonitrile: sterile H2O, and 10 μL was added to either a
microcentrifuge tube or an HPLC vial. Each type of vessel required a base liquid volume, to
ensure that the HPLC injection needle could remove the full volume of injection without taking
up any bubbles. If a microcentrifuge tube was used, then 30 μL of sterile H20 was used. If an
HPLC vial was used, 25 μL of sterile H20 was used.
First, 5 μL of sample was injected onto a semi-prep column (Phenomenex Luna 5 μM
C18(2) 100Å LC 250 x 10 mm column) and eluted using a gradient (beginning at 20% buffer B
(0.1% formic acid in acetonitrile), 80% buffer A (0.1% formic acid in 95% nanopure H2O, 5%
acetonitrile)). A UV-Vis spectrum of the elution profile was collected (“initial spectrum”). Data
was collected for every wavelength between 200 nm – 700 nm, and was visualized at whichever
18

wavelength provided clearest visualization of peaks. Then, another 5 μL was injected, and eluted
using the same method, and the peak(s) most likely to be the peptide of interest were collected in
clean, labelled screw-cap vials. Peaks were judged based on their size, and to a lesser extent,
their elution time.
A 5 μL aliquot of each peak collection was added to a new microcentrifuge tube or
HPLC vial with the proper base of sterile H2O, and 5 μL of each diluted sample was injected
onto the analytical column (Phenomenex Aeris 3.6 μM WIDEPORE C4 200Å LC 150 x 21 mm
column), which was eluted onto the mass spectrometer to confirm presence of the desired
peptide in that peak.
Then, enough crude peptide solution for several injections was added to the original
microcentrifuge tube or HPLC vial. Depending on the estimated concentration of the crude
peptide solution, several injections of volume 5 μL -100 μL were run in series, and the
appropriate peaks were collected in the appropriate screw-cap vials. This was repeated until no
crude peptide solution remained. Once the sample in the microcentrifuge tube or HPLC vial was
at the base liquid volume, additional 1:1 acetonitrile: sterile H20 was added to the sample to
dilute the peptide and allow for further injections. This was repeated until the UV-Vis signal was
at sufficiently low intensity, indicating that most of the peptide had been collected (Figure 12D).
Peptide Storage. Following purification, or in the case that purification could not be completed,
the acetonitrile was removed from each purified or crude peptide solution via vacuum
evaporation (Figure 12D). Then, the solution was frozen in dry ice at an angle, in order to
maximize exposed surface area within the labelled screw-cap vial. The cap of the vial was then
replaced with a porous Kim Wipe, which was secured with a rubber band, and the water was
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removed via lyophilization. After lyophilization, the caps were replaced on the screw-cap vials
and powdered peptides were stored at 4 ℃.

Synthesis of the unnatural amino acid T*. N-Boc-S-Trityl-(D)-Cysteine (Bis-protected Cysteine)
was used as a starting material (Figure 6B). The planned synthetic scheme was four steps: First,
reduction of the carboxylic acid C-terminus to a primary alcohol. Second, the oxidation of that
primary alcohol to an aldehyde. Third, the nucleophilic alkylation of the aldehyde, to mimic the
side chain of threonine. Fourth, deprotection of the N-Boc group. The synthesis would be
followed by deprotection of the S-Trityl group, and finally, the addition of the resultant unnatural
amino acid (T*) to the C-terminus of an LPA peptide, using solid phase peptide synthesis. The
structure of the LPAT* peptide is shown in Figure 6C.

Synthetic step one for T*. Bis-protected Cysteine (1 g, or 0.002157 mol) was dissolved in 5 mL
of anhydrous THF in anhydrous conditions under argon gas. Molar excess of BH3-THF complex
was added, slowly, via syringe, at 0 °C. The mixture was allowed to react, with stirring, for 20
minutes at 0 °C. It was then allowed to react for 1 hour, with stirring, at room temperature
(approximately 25 °C). Then, the reaction was quenched with molar excess methanol and
concentrated. The quenching step was performed twice to ensure full deactivation of the BH3.

Purification of T* intermediate. A small portion of the crude product was saved as a control for
thin layer chromatography (TLC) monitoring of the purification. A flash-column
chromatography column was used to purify the crude product. The column was packed with
20

SiliaFlash P60, 40-63 μm irregular silica gel (SiliCycle) as the stationary media, and run in a
glass column with a 1 L bulb. Laboratory-grade sand (Macron Fine Chemicals) was used as a
filter at the top and bottom of the silica layer, and cotton was used as a porous plug at the bottom
of the column. A 1:1 Methane: Hexanes solution was used as the mobile media to elute the
reduced cysteine product off the column. Fractions of approximate volume 36 mL were collected
in borosilicate glass disposable culture tubes.

Nuclear Magnetic Resonance (NMR) Spectroscopy. NMR spectra were collected on either a
Varian MercuryPlus 300 MHz FT-NMR instrument or a Bruker Avance III 500 MHz FT-NMR
instrument, at Western Washington University. All NMR samples were in Chloroform-D
solvent.
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Supporting Information

A

B

Figure S1. A. Workflow of protein expression and retrieval from bacterial cells B. Workflow
of protein purification.

25

Figure S2. Simplified scheme of one round of the amino acid addition in solid phase
peptide synthesis.
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A

B

C

D

Figure S3. Workflow of laboratory procedure for solid phase peptide synthesis A. Workflow
of Fmoc deprotection. B. Workflow of amino acid preparation for conjugation. C. Workflow
of resin/peptide and amino acid conjugation. D. Workflow of peptide cleavage from resin, and
purification.
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